AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30461089
Drug: Sufficient maternal
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufficient maternal vitamin D status (25Hydroxyvitamin D ≥ 30 ng/mL) during early and late pregnancy
Trial: 29143400
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg intranasal naloxone
Trial: 29143400
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intranasal naloxone
Trial: 29143400
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg intranasal naloxone
Trial: 29143400
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg intramuscular naloxone (reference)
Trial: 29143400
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg intravenous naloxone
Trial: 29143400
Drug: Intranasal naloxone
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal naloxone (1 mg, 2 mg, 4 mg)
Trial: 27145977
Drug: Intramuscular naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular naloxone (0.4 mg)
Trial: 29143400
Drug: Simulation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulation of repeat dosing (2 x 2 mg i.n. vs 5 x 0.4 mg i.m.)
Trial: 23101743
Drug: Antipsychotic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication plus parent training (COMB)
Trial: 23101743
Drug: Antipsychotic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication alone (MED)
Trial: 19640231
Drug: Analgesia injection
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesia injection
Trial: 11884252
Drug: SonoVue (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SonoVue (0.5, 1, 2, and 4 ml)
Trial: 11884252
Drug: SonoVue (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SonoVue (cumulative 7.5 ml dose)
Trial: 11884252
Drug: SonoVue (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SonoVue (2.0 ml dose)
Trial: 11884252
Drug: Albunex (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albunex (two injections)
Trial: 1964620
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg four times daily)
Trial: 7788518
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release theophylline (maximum daily dose 13 mg/kg)
Trial: 2086794
Drug: Interrupted transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interrupted transdermal technique
Trial: 30964423
Drug: sICM (7.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sICM (7.2 g iodine) at 100 kVp
Trial: 30964423
Drug: rICM (5.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rICM (5.4 g iodine) at 100 kVp
Trial: 19858762
Drug: MDD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDD treatment (specific treatments not detailed, included pharmacological and cognitive-behavioral therapy)
Trial: 19858762
Drug: Specific treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific treatments (pharmacological or cognitive-behavioral therapy)
Trial: 17354027
Drug: Intravenous phospholipid
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous phospholipid (PL) infusion (200 mg/kg) weekly for 8 weeks
Trial: 17354027
Drug: Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo infusion
Trial: 15466720
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (for lateral pillar B and B/C border groups)
Trial: 15466720
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (for lateral pillar B and B/C border groups)
Trial: 15466720
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (for lateral pillar group C)
Trial: 15466720
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (for lateral pillar group C)
Trial: 12102158
Drug: Longer delays
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer delays in diagnosis and treatment
Trial: 12102158
Drug: Shorter waiting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shorter waiting times in diagnosis and treatment
Trial: 10682561
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nylestriol
Trial: 1082365
Drug: Schedule 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule 1: single intravenous push of cytosine arabinoside followed by oral methotrexate and intravenous vincristine, cycle repeated every 7 days.
Trial: 1082365
Drug: Schedule 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule 2: three daily injections of cytosine arabinoside followed by vincristine and methotrexate, cycle repeated every 10 days.
Trial: 30551218
Drug: Antidepressant users
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant users
Trial: 30551218
Drug: No use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No use of antidepressants before IBD onset
Trial: 30060719
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine (8 mL injected)
Trial: 30060719
Drug: Oral pain
RxNorm normalized name: Oral Pain Relief
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pain medication alone (Control)
Trial: 24730361
Drug: 0.5 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL/kg of 24% sucrose with a pacifier
Trial: 24730361
Drug: 0.5 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL/kg of sterile water with a pacifier
Trial: 20585813
Drug: Intravenous DEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous DEX 0.3 μg kg⁻¹
Trial: 17507354
Drug: Death or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Death or appropriate ICD therapy
Trial: 9809861
Drug: Hydroxyzine (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine (12.5 mg morning and mid-day, 25 mg evening)
Trial: 9809861
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three capsules/day)
Trial: 9809861
Drug: Buspirone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (5 mg morning and mid-day, 10 mg evening)
Trial: 2711309
Drug: Phenytoin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin (15 mg/kg) administered intravenously shortly before surgery completion and 5‐6 mg/kg/day in three divided doses for the first 3 postoperative days.
Trial: 2711309
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered under identical conditions to the control group of 185 patients.
Trial: 4002788
Drug: muzolimine 30
RxNorm normalized name: Muzolimine
DrugBank: Muzolimine (DB13801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: muzolimine 30 mg
Trial: 598405
Drug: furosemide 40
RxNorm normalized name: furosemide 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: furosemide 40 mg
Trial: 31377052
Drug: Alirocumab 75/150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75/150 mg Q2W
Trial: 12609561
Drug: CR BNO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR BNO 1055 (daily dose corresponding to 40 mg herbal drug)
Trial: 12609561
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (0.6 mg)
Trial: 7911271
Drug: Immediate-release nisoldipine
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate-release nisoldipine (20 mg twice daily)
Trial: 2821477
Drug: Experimental rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental rotavirus vaccine
Trial: 12564024
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug treatment
Trial: 29436142
Drug: AXOS (9.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXOS (9.4 g)
Trial: 29436142
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 g maltodextrin + 1 g unlabelled lactose ureide)
Trial: 18712409
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition supplemented with alanyl-glutamine dipeptide (Gln)
Trial: 18712409
Drug: Regular parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular parenteral nutrition (Control)
Trial: 1980542
Drug: Neuroleptic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic treatment under open conditions
Trial: 1980542
Drug: Neuroleptic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic treatment under double-blind conditions
Trial: 7448103
Drug: Pancuronium 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.01 mg kg‐1
Trial: 7448103
Drug: Pancuronium 0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.015 mg kg‐1
Trial: 7448103
Drug: Pancuronium 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.02 mg kg‐1
Trial: 7448103
Drug: Gallamine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallamine 0.3 mg kg‐1
Trial: 31510871
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dexmedetomidine 0.5 μg/kg and dexamethasone 5 mg
Trial: 28371868
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy including classical needle acupuncture
Trial: 28371868
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy without classical needle acupuncture
Trial: 19037756
Drug: 17 mg
RxNorm normalized name: vitamin B6 17 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 mg Polaprezinc daily for 12 weeks
Trial: 19037756
Drug: 34 mg
RxNorm normalized name: lysine 334 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 34 mg Polaprezinc daily for 12 weeks
Trial: 19037756
Drug: 68 mg
RxNorm normalized name: pyrantel 68 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68 mg Polaprezinc daily for 12 weeks
Trial: 15251273
Drug: 5 mg/16
RxNorm normalized name: nicotine 5 mg/16 hr transdermal film, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/16 h nicotine patches (Nicorette)
Trial: 7936730
Drug: Analgesic upon
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic upon onset of sensation
Trial: 7936730
Drug: Analgesic upon
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic upon onset of pain
Trial: 2975448
Drug: 2.5, 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5, 5, 10, or 20 micrograms dose of recombinant yeast-derived hepatitis B vaccine
Trial: 2975448
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms dose of plasma-derived vaccine
Trial: 2975448
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms booster dose of recombinant vaccine
Trial: 31838010
Drug: Ribociclib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib (600 mg once daily for 3 weeks on, 1 week off) plus daily letrozole (2·5 mg/day) for 24 weeks
Trial: 31838010
Drug: Chemotherapy (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days followed by weekly paclitaxel 80 mg/m2 for 12 weeks) for 24 weeks
Trial: 29674370
Drug: 2 g dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g dose of cephalexin administered 40‐60 min prior to surgery
Trial: 28339576
Drug: Post-treatment e-cigarette
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment e-cigarette users
Trial: 16517274
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine (Control)
Trial: 14753593
Drug: Monophasic injection
RxNorm normalized name: Monobasic Potassium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic injection protocol (123 mL at 2.5 mL/s)
Trial: 14753593
Drug: Biphasic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biphasic injection protocol (123 mL, 60 mL at 1.5 mL/s and then 63 mL at 2.5 mL/s)
Trial: 14753593
Drug: Sigmoid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sigmoid injection protocol (0.6 mL/s ending at 2.5 mL/s)
Trial: 1600772
Drug: Greatest response-invoking
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Greatest response-invoking agent (specific agent not mentioned)
Trial: 1600772
Drug: Least response-invoking
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Least response-invoking agent (specific agent not mentioned)
Trial: 25253665
Drug: LIPO-5 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIPO-5 (250 μg)
Trial: 25253665
Drug: ALVAC-HIV (vCP1452)
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALVAC-HIV (vCP1452) + LIPO-5 (250, 750, and 2,500 μg)
Trial: 2952396
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of vitamin C daily
Trial: 20303119
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg solifenacin once daily
Trial: 20303119
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oxybutynin immediate release 3 times daily
Trial: 15726875
Drug: Benfotiamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benfotiamine (50 mg tablets, four times daily for three weeks)
Trial: 2567670
Drug: Metoprolol (M,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (M, 100 mg)
Trial: 2567670
Drug: Pindolol (P,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (P, 10 mg)
Trial: 23246919
Drug: Previous hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous hormone therapy (HT) use
Trial: 27387522
Drug: Adaptive servo-ventilation
RxNorm normalized name: Servo Stat Bac
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adaptive servo-ventilation (ASV) therapy
Trial: 23250911
Drug: Non-ASV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ASV treatment (control group)
Trial: 21955700
Drug: ASV therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASV therapy
Trial: 2882773
Drug: temelastine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: temelastine 100 mg
Trial: 26712942
Drug: Topical DFMO
RxNorm normalized name: DFMO
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical DFMO applied twice daily
Trial: 26712942
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac applied daily
Trial: 24823430
Drug: Cognitive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive group therapy combined with pharmacotherapy
Trial: 24823430
Drug: Happiness training
RxNorm normalized name: Happy Cappy
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Happiness training combined with pharmacotherapy
Trial: 22192331
Drug: Pharmacotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy only
Trial: 20508081
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro protamine suspension (ILPS) 0.6 U/kg
Trial: 20508081
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 0.6 U/kg
Trial: 15802149
Drug: Home cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home cancer healthcare program (chemotherapy)
Trial: 22124104
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus surgery
Trial: 7358211
Drug: Piracetam (4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (4.8 g per day for 4 days and 7.2 g on the 5th day)
Trial: 31668556
Drug: Wet cupping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet cupping therapy (WCT) applied once a month for 12 months (Group 2)
Trial: 25557762
Drug: interleukin 2
RxNorm normalized name: Recombinant interleukin 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: interleukin 2 receptor antagonists (IL‐2RA)
Trial: 22080012
Drug: Normal vaccination
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal vaccination (simplified vaccination + second dose of ND‐IB, H120, and AI)
Trial: 16807618
Drug: Eprosartan 600
RxNorm normalized name: eprosartan 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 600 mg tablet once daily for 10 weeks
Trial: 8262292
Drug: Amox‐CA (Augmentin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amox‐CA (Augmentin) 1.2 g intravenous injection, 1 hour after delivery
Trial: 18390558
Drug: Accelerated fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated fractionation radiation therapy (2.4 Gy/fr)
Trial: 18390558
Drug: Conventional fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionation radiation therapy (2 Gy/fr)
Trial: 15988102
Drug: cilostazol +
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cilostazol + aspirin (C group)
Trial: 15988102
Drug: ticlopidine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ticlopidine + aspirin (T group)
Trial: 10774681
Drug: Combination regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimens of artemether/pyrimethamine (1‐, 2‐ and 3‐day regimens)
Trial: 1649863
Drug: Atenolol (antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (antihypertensive drug treatment group)
Trial: 6858934
Drug: Pirmenol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirmenol (50 mg priming bolus over 2 minutes, followed by 2.5 mg/min for 1 hour, and 0.25 mg/min maintenance infusion)
Trial: 27957632
Drug: Antiepileptic drug
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drug (AED) treatment
Trial: 27957632
Drug: Non-AED treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-AED treatment (Control)
Trial: 27957632
Drug: Subgroup analysis
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup analysis of patients with subcortical calcifications (AED treatment)
Trial: 26821625
Drug: Chlorthalidone, 6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone, 6.25 mg daily
Trial: 26821625
Drug: HCTZ, 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ, 12.5 mg daily
Trial: 26821625
Drug: HCTZ-CR, 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ-CR, 12.5 mg daily
Trial: 23405799
Drug: Yangjing Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangjing Capsule (5 pills, tid) plus low-dose tadalafil (5 mg, qd, 1 h before bedtime)
Trial: 23405799
Drug: Oral ephedrine
RxNorm normalized name: ephedrine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ephedrine (25 mg before bedtime)
Trial: 17503670
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg Suc-HSA (single dose)
Trial: 17503670
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg Suc-HSA (single dose)
Trial: 17503670
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg Suc-HSA (multiple doses)
Trial: 12470517
Drug: 585 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 585 nm laser treatment at subpurpura energy level
Trial: 12470517
Drug: Second treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second treatment with 585 nm laser 2 weeks later